Investigators from Mass General Brigham​ have found that a method originally designed for cancer detection can also identify and monitor even tiny amounts of SARS-CoV-2 intact viral particles in blood and other fluids from patients with acute COVID-19 infections, creating the potential for guiding future treatment of patients.